-
3
-
-
84919999219
-
Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes
-
Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2015;38:140-9.
-
(2015)
Diabetes Care
, vol.38
, pp. 140-149
-
-
Inzucchi, S.E.1
Bergenstal, R.M.2
Buse, J.B.3
-
4
-
-
84961289782
-
Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes
-
Shiramoto M, Eto T, Irie S, et al. Single-dose new insulin glargine 300 U/ml provides prolonged, stable glycaemic control in Japanese and European people with type 1 diabetes. Diabetes Obes Metab 2015;17:254-60.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 254-260
-
-
Shiramoto, M.1
Eto, T.2
Irie, S.3
-
5
-
-
84905721701
-
Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml
-
Steinstraesser A, Schmidt R, Bergmann K, et al. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab 2014;16:873-6.
-
(2014)
Diabetes Obes Metab
, vol.16
, pp. 873-876
-
-
Steinstraesser, A.1
Schmidt, R.2
Bergmann, K.3
-
6
-
-
84908179629
-
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1)
-
Riddle MC, Bolli GB, Ziemen M, et al., EDITION 1 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care 2014;37:2755-62.
-
(2014)
Diabetes Care
, vol.37
, pp. 2755-2762
-
-
Riddle, M.C.1
Bolli, G.B.2
Ziemen, M.3
-
7
-
-
84910033227
-
New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents andbasal insulin: Glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2)
-
Yki-Järvinen H, Bergenstal R, Ziemen M, et al., EDITION 2 Study Investigators. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents andbasal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care 2014;37:3235-43.
-
(2014)
Diabetes Care
, vol.37
, pp. 3235-3243
-
-
Yki-Järvinen, H.1
Bergenstal, R.2
Ziemen, M.3
-
8
-
-
84924731879
-
New insulin glargine 300 U/mL compared with glargine 100 U/mL ininsulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: A randomized controlled trial (EDITION 3)
-
Bolli GB, Riddle MC, Bergenstal RM, et al., on behalf of the EDITION 3 study investigators. New insulin glargine 300 U/mL compared with glargine 100 U/mL ininsulin-naïve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab 2015;17:386-94.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 386-394
-
-
Bolli, G.B.1
Riddle, M.C.2
Bergenstal, R.M.3
-
11
-
-
66549123433
-
DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: Safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes
-
Buse JB, Wolffenbuttel BH, Herman WH, et al. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. Diabetes Care 2009;32:1007-13.
-
(2009)
Diabetes Care
, vol.32
, pp. 1007-1013
-
-
Buse, J.B.1
Wolffenbuttel, B.H.2
Herman, W.H.3
-
12
-
-
73349140858
-
Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study
-
Fritsche A, Larbig M, Owens D, et al. Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study. Diabetes Obes Metab 2010;12:115-23.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 115-123
-
-
Fritsche, A.1
Larbig, M.2
Owens, D.3
-
13
-
-
77957279506
-
Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: Initiate and progressively advance insulin therapy in type 2 diabetes
-
Jain SM, Mao X, Escalante-Pulido M, et al. Prandial-basal insulin regimens plus oral antihyperglycaemic agents to improve mealtime glycaemia: initiate and progressively advance insulin therapy in type 2 diabetes. Diabetes Obes Metab 2010;12:967-75.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 967-975
-
-
Jain, S.M.1
Mao, X.2
Escalante-Pulido, M.3
-
14
-
-
33845317568
-
Starting insulin therapy in type 2 diabetes: Twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride
-
Kann PH, Wascher T, Zackova V, et al. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride. Exp Clin Endocrinol Diabetes 2006;114:527-32.
-
(2006)
Exp Clin Endocrinol Diabetes
, vol.114
, pp. 527-532
-
-
Kann, P.H.1
Wascher, T.2
Zackova, V.3
-
15
-
-
33748263029
-
Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. Basal therapy with insulin glargine: A randomized controlled trial in patients with type 2 diabetes beginning insulin therapy
-
Kazda C, Hulstrunk H, Helsberg K, et al. Prandial insulin substitution with insulin lispro or insulin lispro mid mixture vs. basal therapy with insulin glargine: a randomized controlled trial in patients with type 2 diabetes beginning insulin therapy. J Diabetes Complicat 2006;20:145-52.
-
(2006)
J Diabetes Complicat
, vol.20
, pp. 145-152
-
-
Kazda, C.1
Hulstrunk, H.2
Helsberg, K.3
-
16
-
-
79952384658
-
A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: A randomized, open-label study
-
Ligthelm RJ, Gylvin T, De Luzio T, et al. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study. Endocr Pract 2011;17:41-50.
-
(2011)
Endocr Pract
, vol.17
, pp. 41-50
-
-
Ligthelm, R.J.1
Gylvin, T.2
De Luzio, T.3
-
17
-
-
12844265257
-
Initiating insulin therapy in type 2 Diabetes: A comparison of biphasic and basal insulin analogs
-
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28:260-5.
-
(2005)
Diabetes Care
, vol.28
, pp. 260-265
-
-
Raskin, P.1
Allen, E.2
Hollander, P.3
-
18
-
-
84871445772
-
Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: Twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine
-
Riddle MC, Vlajnic A, Jones B, et al. Comparison of 3 intensified insulin regimens added to oral therapy for type 2 diabetes: twice-daily aspart premixed vs glargine plus 1 prandial glulisine or stepwise addition of glulisine to glargine. Diabetes 2011;60(Suppl 1):A113.
-
(2011)
Diabetes
, vol.60
, pp. A113
-
-
Riddle, M.C.1
Vlajnic, A.2
Jones, B.3
-
19
-
-
37449017989
-
1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: A multinational, 24-week, randomized, open-label, parallel-group comparison
-
1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. Clin Ther 2007;29:2349-64.
-
(2007)
Clin Ther
, vol.29
, pp. 2349-2364
-
-
Robbins, D.C.1
Beisswenger, P.J.2
Ceriello, A.3
-
20
-
-
38149073314
-
Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: Prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy
-
Rosenstock J, Ahmann AJ, Colon G, et al. Advancing insulin therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. Diabetes Care 2008;31:20-5.
-
(2008)
Diabetes Care
, vol.31
, pp. 20-25
-
-
Rosenstock, J.1
Ahmann, A.J.2
Colon, G.3
-
21
-
-
72549114224
-
Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: An open-label, multinational RCT
-
Strojek K, Bebakar WMW, Khutsoane DT, et al. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. Curr Med Res Opin 2009;25:2887-94.
-
(2009)
Curr Med Res Opin
, vol.25
, pp. 2887-2894
-
-
Strojek, K.1
Bebakar, W.M.W.2
Khutsoane, D.T.3
-
24
-
-
0038131919
-
Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial
-
Fritsche A, Schweitzer MA, Haring H-U, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine Hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003;138:952-9.
-
(2003)
Ann Intern Med
, vol.138
, pp. 952-959
-
-
Fritsche, A.1
Schweitzer, M.A.2
Haring, H.-U.3
-
25
-
-
0038292180
-
A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes
-
Massi Benedetti M, Humburg E, Dressler A, et al. A one-year, randomised, multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with type 2 diabetes. Horm Metab Res 2003;35:189-96.
-
(2003)
Horm Metab Res
, vol.35
, pp. 189-196
-
-
Massi Benedetti, M.1
Humburg, E.2
Dressler, A.3
-
26
-
-
0242269000
-
The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients
-
Riddle MC, Rosenstock J, Gerich J. Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26:3080-6.
-
(2003)
Diabetes Care
, vol.26
, pp. 3080-3086
-
-
Riddle, M.C.1
Rosenstock, J.2
Gerich, J.3
-
27
-
-
0034827469
-
Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin
-
Rosenstock J, Schwartz SL, Clark CM Jr, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001;24:631-6.
-
(2001)
Diabetes Care
, vol.24
, pp. 631-636
-
-
Rosenstock, J.1
Schwartz, S.L.2
Clark, C.M.3
-
28
-
-
68449099924
-
Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: A long-term, randomised, open-label study
-
Rosenstock J, Fonseca V, McGill JB, et al. Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia 2009;52:1778-88.
-
(2009)
Diabetologia
, vol.52
, pp. 1778-1788
-
-
Rosenstock, J.1
Fonseca, V.2
McGill, J.B.3
-
29
-
-
33244479164
-
Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study
-
Yki-Järvinen H, Kauppinen-Makelin R, Tiikkainen M, et al. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006;49:442-51.
-
(2006)
Diabetologia
, vol.49
, pp. 442-451
-
-
Yki-Järvinen, H.1
Kauppinen-Makelin, R.2
Tiikkainen, M.3
-
30
-
-
84859921058
-
Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): A phase 3, randomised, open-label, treat-to-target non-inferiority trial
-
Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-long acting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet 2012;379:1498-507.
-
(2012)
Lancet
, vol.379
, pp. 1498-1507
-
-
Garber, A.J.1
King, A.B.2
Del Prato, S.3
-
31
-
-
84889648892
-
Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: A 26-week, randomized, controlled, multinational, treat-to-target trial: The BEGIN LOW VOLUME trial
-
Gough SC, Bhargava A, Jain R, et al. Low-volume insulin degludec 200 units/ml once daily improves glycemic control similarly to insulin glargine with a low risk of hypoglycemia in insulin-naive patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN LOW VOLUME trial. Diabetes Care 2013;36:2536-42.
-
(2013)
Diabetes Care
, vol.36
, pp. 2536-2542
-
-
Gough, S.C.1
Bhargava, A.2
Jain, R.3
-
32
-
-
84875444482
-
The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: A 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes
-
Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013;36:858-64.
-
(2013)
Diabetes Care
, vol.36
, pp. 858-864
-
-
Meneghini, L.1
Atkin, S.L.2
Gough, S.C.L.3
-
33
-
-
84869842163
-
Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: A 1-year, randomized, treat-to-target trial (BEGIN Once Long)
-
Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care 2012;35:2464-71.
-
(2012)
Diabetes Care
, vol.35
, pp. 2464-2471
-
-
Zinman, B.1
Philis-Tsimikas, A.2
Cariou, B.3
-
34
-
-
84884502135
-
Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: Results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials
-
Zinman B, De Vries JH, Bode B, et al. Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes Endocrinol 2013;1:123-31.
-
(2013)
Lancet Diabetes Endocrinol
, vol.1
, pp. 123-131
-
-
Zinman, B.1
De Vries, J.H.2
Bode, B.3
-
35
-
-
57649230070
-
A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes
-
Hollander P, Cooper J, Bregnhoj J, et al. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008;30:1976-87.
-
(2008)
Clin Ther
, vol.30
, pp. 1976-1987
-
-
Hollander, P.1
Cooper, J.2
Bregnhoj, J.3
-
36
-
-
84879799134
-
Once-daily initiation of basal insulin as add-on to metformin: A 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes
-
Meneghini L, Kesavadev J, Demissie M, et al. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Diabetes Obes Metab 2013;15:729-36.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 729-736
-
-
Meneghini, L.1
Kesavadev, J.2
Demissie, M.3
-
37
-
-
70350605350
-
Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes
-
Raskin P, Gylvin T, Weng W, et al. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. Diabetes Metab Res Rev 2009;25:542-8.
-
(2009)
Diabetes Metab Res Rev
, vol.25
, pp. 542-548
-
-
Raskin, P.1
Gylvin, T.2
Weng, W.3
-
38
-
-
39049105019
-
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
-
Rosenstock J, Davies M, Home PD, et al. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetologia 2008;51:408-16.
-
(2008)
Diabetologia
, vol.51
, pp. 408-416
-
-
Rosenstock, J.1
Davies, M.2
Home, P.D.3
-
39
-
-
77954255771
-
A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs
-
Swinnen SG, Dain MP, Aronson R, et al. A 24-week, randomized, treat-to-target trial comparing initiation of insulin glargine once-daily with insulin detemir twice-daily in patients with type 2 diabetes inadequately controlled on oral glucose-lowering drugs. Diabetes Care 2010;33:1176-8.
-
(2010)
Diabetes Care
, vol.33
, pp. 1176-1178
-
-
Swinnen, S.G.1
Dain, M.P.2
Aronson, R.3
-
40
-
-
35548947584
-
Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes
-
Holman RR, Thorne KI, Farmer AJ, et al. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. N Engl J Med 2007;357:1716-30.
-
(2007)
N Engl J Med
, vol.357
, pp. 1716-1730
-
-
Holman, R.R.1
Thorne, K.I.2
Farmer, A.J.3
-
41
-
-
58149177354
-
Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: A randomized controlled trial
-
Liebl A, Prager R, Binz K, et al., PREFER Study Group. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. Diabetes Obes Metab 2009;11:45-52.
-
(2009)
Diabetes Obes Metab
, vol.11
, pp. 45-52
-
-
Liebl, A.1
Prager, R.2
Binz, K.3
-
42
-
-
12744274870
-
Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes
-
Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
-
(2005)
Diabetes Obes Metab
, vol.7
, pp. 56-64
-
-
Haak, T.1
Tiengo, A.2
Draeger, E.3
-
43
-
-
33746391488
-
A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes
-
Hermansen K, Davies M, Derezinski T, et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006;29:1269-74.
-
(2006)
Diabetes Care
, vol.29
, pp. 1269-1274
-
-
Hermansen, K.1
Davies, M.2
Derezinski, T.3
-
44
-
-
48249139906
-
Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: The PREDICTIVE BMI clinical trial
-
Montañana CF, Herrero CH, Fernandez MR. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight type 2 diabetes patients: the PREDICTIVE BMI clinical trial. Diabet Med 2008;25:916-23.
-
(2008)
Diabet Med
, vol.25
, pp. 916-923
-
-
Montañana, C.F.1
Herrero, C.H.2
Fernandez, M.R.3
-
45
-
-
33845236398
-
Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes
-
Philis-Tsimikas A, Charpentier G, Clauson P, et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006;28:1569-81.
-
(2006)
Clin Ther
, vol.28
, pp. 1569-1581
-
-
Philis-Tsimikas, A.1
Charpentier, G.2
Clauson, P.3
-
46
-
-
6944244979
-
Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes
-
Raslová K, Bogoev M, Raz I, et al. Insulin detemir and insulin aspart: a promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004;66:193-201.
-
(2004)
Diabetes Res Clin Pract
, vol.66
, pp. 193-201
-
-
Raslová, K.1
Bogoev, M.2
Raz, I.3
-
47
-
-
12844276465
-
Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes
-
Janka H, Plewe G, Riddle M, et al. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28:254-9.
-
(2005)
Diabetes Care
, vol.28
, pp. 254-259
-
-
Janka, H.1
Plewe, G.2
Riddle, M.3
-
48
-
-
77955094348
-
Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: Results from the durable trial
-
Lee LJ, Fahrbach JL, Nelson LM, et al. Effects of insulin initiation on patient-reported outcomes in patients with type 2 diabetes: results from the durable trial. Diabetes Res Clin Pract 2010;89:157-66.
-
(2010)
Diabetes Res Clin Pract
, vol.89
, pp. 157-166
-
-
Lee, L.J.1
Fahrbach, J.L.2
Nelson, L.M.3
-
49
-
-
33846254561
-
Basal insulin or premix analogue therapy in type 2 diabetes patients
-
Raskin PR, Hollander PA, Lewin A, et al. Basal insulin or premix analogue therapy in type 2 diabetes patients. Eur J Intern Med 2007;18:56-62.
-
(2007)
Eur J Intern Med
, vol.18
, pp. 56-62
-
-
Raskin, P.R.1
Hollander, P.A.2
Lewin, A.3
-
50
-
-
0033867021
-
Less nocturnalhypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group
-
Yki-Järvinen H, Dressler A, Ziemen M, HOE 901/300s Study Group. Less nocturnalhypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care 2000;23:1130-6.
-
(2000)
Diabetes Care
, vol.23
, pp. 1130-1136
-
-
Yki-Järvinen, H.1
Dressler, A.2
Ziemen, M.3
-
51
-
-
84929019522
-
New insulinglargine 300 Units mL-1 provides a more even activity profile and prolongedglycemic control at steady state compared with insulin glargine 100 Units mL-1
-
Becker RH, Dahmen R, Bergmann K, et al. New insulinglargine 300 Units mL-1 provides a more even activity profile and prolongedglycemic control at steady state compared with insulin glargine 100 Units mL-1. Diabetes Care 2015;38:637-43.
-
(2015)
Diabetes Care
, vol.38
, pp. 637-643
-
-
Becker, R.H.1
Dahmen, R.2
Bergmann, K.3
-
52
-
-
47649100195
-
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: A meta-analysis
-
Monami M, Marchionni N, Mannucci E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 2008;81:184-9.
-
(2008)
Diabetes Res Clin Pract
, vol.81
, pp. 184-189
-
-
Monami, M.1
Marchionni, N.2
Mannucci, E.3
-
53
-
-
77955031968
-
Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine
-
Home PD, Fritsche A, Schinzel S, et al. Meta-analysis of individual patient data to assess the risk of hypoglycaemia in people with type 2 diabetes using NPH insulin or insulin glargine. Diabetes Obes Metab 2010;12:772-9.
-
(2010)
Diabetes Obes Metab
, vol.12
, pp. 772-779
-
-
Home, P.D.1
Fritsche, A.2
Schinzel, S.3
-
54
-
-
84939572199
-
Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: Glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes
-
Ritzel R, Roussel R, Bolli GB, et al. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab 2015;17:859-67.
-
(2015)
Diabetes Obes Metab
, vol.17
, pp. 859-867
-
-
Ritzel, R.1
Roussel, R.2
Bolli, G.B.3
-
55
-
-
84887200674
-
A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes
-
Freemantle N, Balkau B, Home PD. A propensity score matched comparison of different insulin regimens 1 year after beginning insulin in people with type 2 diabetes. Diabetes Obes Metab 2013;15:1120-7.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 1120-1127
-
-
Freemantle, N.1
Balkau, B.2
Home, P.D.3
-
56
-
-
84908689468
-
The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes
-
Edelman SV, Blose JS. The impact of nocturnal hypoglycemia on clinical and cost-related issues in patients with type 1 and type 2 diabetes. Diabetes Educ 2014;40:269-79.
-
(2014)
Diabetes Educ
, vol.40
, pp. 269-279
-
-
Edelman, S.V.1
Blose, J.S.2
-
57
-
-
84877340173
-
A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function
-
Brod M, Wolden M, Christensen T, et al. A nine country study of the burden of non-severe nocturnal hypoglycaemic events on diabetes management and daily function. Diabetes Obes Metab 2013;15:546-57.
-
(2013)
Diabetes Obes Metab
, vol.15
, pp. 546-557
-
-
Brod, M.1
Wolden, M.2
Christensen, T.3
-
58
-
-
84890313541
-
Understanding the economic burden of nonsevere nocturnal hypoglycemic events: Impact on work productivity, disease management, and resource utilization
-
Brod M, Wolden M, Christensen T, et al. Understanding the economic burden of nonsevere nocturnal hypoglycemic events: impact on work productivity, disease management, and resource utilization. Value Health 2013;16:1140-9.
-
(2013)
Value Health
, vol.16
, pp. 1140-1149
-
-
Brod, M.1
Wolden, M.2
Christensen, T.3
-
59
-
-
84898648419
-
Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: A meta-analysis of 5 randomized begin trials
-
Rodbard HW, Gough S, Lane W, et al. Reduced risk of hypoglycemia with insulin degludec versus insulin glargine in patients with type 2 diabetes requiring high doses of Basal insulin: a meta-analysis of 5 randomized begin trials. Endocr Pract 2014;20:285-92.
-
(2014)
Endocr Pract
, vol.20
, pp. 285-292
-
-
Rodbard, H.W.1
Gough, S.2
Lane, W.3
-
60
-
-
84937817361
-
Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
-
Rys P, Wojciechowski P, Rogoz-Sitek A, et al. Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol 2015;52:649-62.
-
(2015)
Acta Diabetol
, vol.52
, pp. 649-662
-
-
Rys, P.1
Wojciechowski, P.2
Rogoz-Sitek, A.3
|